Pullen Investment Management LLC Purchases 22,250 Shares of Kenvue Inc. (NYSE:KVUE)

Pullen Investment Management LLC grew its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 46.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 69,907 shares of the company's stock after buying an additional 22,250 shares during the period. Pullen Investment Management LLC's holdings in Kenvue were worth $1,493,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Geneos Wealth Management Inc. acquired a new stake in Kenvue during the 4th quarter valued at $29,000. SRS Capital Advisors Inc. raised its position in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after purchasing an additional 571 shares during the period. Asset Planning Inc bought a new stake in shares of Kenvue during the 4th quarter worth about $42,000. Clarity Asset Management Inc. acquired a new position in Kenvue in the 4th quarter valued at about $45,000. Finally, SBI Securities Co. Ltd. acquired a new position in Kenvue in the 4th quarter valued at about $46,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Price Performance

NYSE:KVUE traded up $0.10 during trading hours on Friday, hitting $23.68. The company's stock had a trading volume of 4,953,993 shares, compared to its average volume of 16,312,075. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $25.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a fifty day simple moving average of $23.26 and a 200-day simple moving average of $22.64. The company has a market capitalization of $45.44 billion, a P/E ratio of 44.69, a PEG ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. The firm had revenue of $3.74 billion during the quarter, compared to analysts' expectations of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The business's revenue for the quarter was down 3.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.28 earnings per share. On average, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were issued a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.46%. Kenvue's dividend payout ratio (DPR) is presently 149.09%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on KVUE shares. Barclays boosted their price objective on Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a report on Monday, May 12th. Canaccord Genuity Group lifted their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Citigroup lifted their price target on shares of Kenvue from $22.00 to $24.50 and gave the company a "neutral" rating in a research report on Friday, May 9th. Royal Bank of Canada restated a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Finally, UBS Group lifted their price objective on Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Friday, May 9th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $25.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.